Lexaria Bioscience Corp. provided a progress update on February 5, 2025, regarding its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. The company has completed its submission to the human research ethics committee (HREC) for the planned addition of Study Arm 5.
This new arm is intended to evaluate the performance of its DehydraTECH-tirzepatide formulation. The decision to add this arm follows positive findings previously achieved and released for Human Pilot Study #3 (GLP-1-H24-3).
This expansion of the study demonstrates Lexaria's confidence in its DehydraTECH technology and its commitment to thoroughly evaluating its potential with key GLP-1 drugs. The ongoing study aims to investigate safety, diabetes control, and weight loss.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.